Determinants of resistance to engineered T-cell therapies targeting CD19 in lymphoma
淋巴瘤中针对 CD19 的工程化 T 细胞疗法耐药性的决定因素
基本信息
- 批准号:10740658
- 负责人:
- 金额:$ 1.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AftercareAntigen TargetingArchitectureB-Cell LymphomasB-LymphocytesBioinformaticsCD19 geneCancer Personalized Profiling by Deep SequencingCandidate Disease GeneCell LineageCell physiologyCellsClinical TrialsDNA Sequence AlterationDataDetectionDevelopmentDisease ProgressionDoctor of PhilosophyExhibitsFoundationsFutureGene ExpressionGene Expression ProfilingGenesGenomicsGoalsHealthImmuneImmunohistochemistryImmunophenotypingImmunotherapyIn VitroInferiorInfusion proceduresKnowledgeLeadLifeLymphomaLymphoma cellMeasurementMediatingMentorshipMethodsMissionModelingMolecularMonitorMutationNatureNon-Hodgkin&aposs LymphomaOrganismOrganoidsOutcomePAX5 genePatient-Focused OutcomesPatientsPhenotypePlasmaPopulationPredictive FactorPrimary NeoplasmProgressive DiseaseRecurrenceRefractoryRelapseResearch PersonnelResistanceRoleSamplingSurfaceSystemT cell therapyT-LymphocyteTechniquesTranslatingTreatment FailureTumor BiologyTumor EscapeTumor TissueTumor-DerivedUnited States National Institutes of HealthUniversitiesadverse outcomebiomarker identificationcancer typecareercell free DNAchimeric antigen receptorchimeric antigen receptor T cellscohortcomputerized toolscytotoxicitydesigndisabilityengineered T cellsexperienceimprovedin vitro Modelinnovationmedical schoolsneoplastic cellnovelpredicting responseprognostic significanceprotein expressionrelapse predictionresistance generesistance mechanismresistance mutationresponsetargeted sequencingtargeted treatmenttherapy developmenttissue culturetooltranscriptome sequencingtreatment responsetreatment strategytumortumor DNAtumor immunologytumor microenvironmenttumor-immune system interactions
项目摘要
Project Summary/Abstract
The outcomes for patients with large B-cell lymphoma (LBCL) that are relapsed or refractory to frontline
therapy remain quite poor. While anti-CD19 chimeric antigen receptor (CAR19) T-cells have emerged as a
promising treatment option for this group of patients, over half of these patients still go on to exhibit disease
progression. The mechanisms through which resistance to CAR19 T-cell therapy develops, and factors
predictive of poor outcomes, have not yet been well characterized. In this proposal we seek to elucidate these
mechanisms with the ultimate goal of informing the design of improved immunotherapies that will result in better
outcomes for patients with LBCL.
Novel methods to profile tumor-derived cell-free DNA from the blood plasma of patients, also referred to
as circulating tumor DNA (ctDNA), have unlocked significant opportunities to monitor treatment response and
study tumor biology both prior to and after therapy. We recently applied one such method called Cancer
Personalized Profiling by Deep Sequencing (CAPP-Seq), a targeted sequencing approach for ctDNA detection
and profiling, to a cohort of patients with LBCL undergoing therapy with the CAR19 platform axicabtagene
ciloleucel (axi-cel). We found that ctDNA levels prior to and following CAR19 T-cell infusion were predictive of
response, and also identified several genes involved in B-cell lineage commitment and determination of the
tumor immune microenvironment that were recurrently altered in patients who developed progressive disease.
In this proposal we will build on this prior data by validating our findings in an independent cohort of
patients undergoing therapy with an alternate CAR19 platform (Aim 1). We will then assess the downstream
effects these alterations have on tumor phenotype and the tumor microenvironment. By integrating gene
expression data and cutting-edge immunophenotyping and computational tools, we will resolve the components
of the intratumoral immune milieu to gain a better understanding of how different immune cell populations
contribute to response and resistance (Aim 2). Finally, we will employ a novel organoid tissue culture system to
directly assess how alterations in these genes effect the interaction between CAR19 T-cells and tumor cells in
the context of an intact immune microenvironment (Aim 3). Ultimately, we hope that these studies will have
implications not only in development of improved CAR19 platforms for lymphoma, but also in the improvement
of immunotherapies for other cancer types as well.
This proposal will be carried out at the Stanford University School of Medicine, under the mentorship of
Ash Alizadeh, MD/PhD. Through completion of this proposal, I will gain the relevant experience in bioinformatics
and tumor immunology to successfully launch a career as an independent investigator focused on developing
and translating new immunotherapies for patients with lymphoma.
项目摘要/摘要
复发或对一线无效的大B细胞淋巴瘤(LBCL)患者的预后
治疗仍然相当糟糕。而抗CD19嵌合抗原受体(CAR19)T细胞已经成为一种
对于这一组患者来说,有希望的治疗方案是,超过一半的患者仍然表现出疾病
进步。CAR19 T细胞治疗耐药的发生机制及其影响因素
对糟糕结果的预测,还没有得到很好的描述。在这项提议中,我们试图澄清这些
机制,最终目标是通知改进的免疫疗法的设计,从而产生更好的
LBCL患者的预后。
从患者血浆中分析肿瘤来源的无细胞DNA的新方法,也参考
作为循环中的肿瘤DNA(CtDNA),释放了监测治疗反应和
在治疗前和治疗后研究肿瘤生物学。我们最近应用了一种名为癌症的方法
一种用于ctDNA检测的靶向测序方法--CAPP-SEQ
以及对一组接受cAR19平台axicabagene治疗的LBCL患者的分析
绒毛(轴细胞)。我们发现,在cAR19 T细胞输注前后ctDNA水平可以预测
并鉴定了几个与B细胞谱系承诺和决定B细胞系的
进展性疾病患者肿瘤免疫微环境反复改变。
在这项提案中,我们将在先前数据的基础上,通过验证我们在独立队列中的发现
接受替代cAR19平台治疗的患者(目标1)。然后我们将对下游进行评估
这些改变对肿瘤表型和肿瘤微环境有影响。通过整合基因
表达数据和尖端的免疫表型和计算工具,我们将解析组件
以更好地了解不同的免疫细胞群如何
有助于应对和抵抗(目标2)。最后,我们将采用一种新的有机组织培养系统来
直接评估这些基因的改变如何影响cAR19 T细胞和肿瘤细胞之间的相互作用
完整免疫微环境的背景(目标3)。最终,我们希望这些研究将有
不仅对改进的淋巴瘤cAR19平台的开发有意义,而且对改进的cAR19平台也有意义
对其他癌症类型的免疫疗法也是如此。
这项提议将在斯坦福大学医学院进行,由
Ash Alizadeh医学博士/博士通过完成这项提案,我将获得生物信息学的相关经验
和肿瘤免疫学成功地启动了职业生涯,成为一名专注于开发
以及为淋巴瘤患者翻译新的免疫疗法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brian Sworder其他文献
Brian Sworder的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brian Sworder', 18)}}的其他基金
Determinants of resistance to engineered T-cell therapies targeting CD19 in lymphoma
淋巴瘤中针对 CD19 的工程化 T 细胞疗法耐药性的决定因素
- 批准号:
10951410 - 财政年份:2023
- 资助金额:
$ 1.54万 - 项目类别:
相似海外基金
Development of novel ABO blood group antigen targeting peptide that suppress rejection during ABO-incompatible kidney transplantation
开发新型 ABO 血型抗原靶向肽,可抑制 ABO 不相容肾移植过程中的排斥反应
- 批准号:
23791736 - 财政年份:2011
- 资助金额:
$ 1.54万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Antigen Targeting in plasmazytoide dendritische Zellen - Nutzung zur Toleranzinduktion und Vakzinierung
浆细胞样树突状细胞中的抗原靶向 - 用于耐受诱导和疫苗接种
- 批准号:
211908646 - 财政年份:2011
- 资助金额:
$ 1.54万 - 项目类别:
Research Grants
Development of Novel Prostate Specific Membrane Antigen Targeting Probes for Prostate Cancer Imaging
开发用于前列腺癌成像的新型前列腺特异性膜抗原靶向探针
- 批准号:
23791413 - 财政年份:2011
- 资助金额:
$ 1.54万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Immunregulation bei entzündlichen Darmerkrankungen durch Antigen Targeting des DEC-205 Rezeptors - Mechanismen und Funktion
通过 DEC-205 受体抗原靶向调节炎症性肠病 - 机制和功能
- 批准号:
168824599 - 财政年份:2010
- 资助金额:
$ 1.54万 - 项目类别:
Research Grants
Anti-tumor vaccine by the use of antigen targeting to lectins expressed on dendritic cells
利用抗原靶向树突状细胞上表达的凝集素的抗肿瘤疫苗
- 批准号:
21790144 - 财政年份:2009
- 资助金额:
$ 1.54万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Development of novel oncofetal antigen targeting immunotherapy for refractory ovarian carcinoma
难治性卵巢癌新型癌胎抗原靶向免疫疗法的开发
- 批准号:
21592127 - 财政年份:2009
- 资助金额:
$ 1.54万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Salmonella type III-mediated antigen targeting to induce cellular immunity: characterzition of effector and memory T cell populations after oral vaccination
沙门氏菌 III 型介导的抗原靶向诱导细胞免疫:口服疫苗接种后效应和记忆 T 细胞群的特征
- 批准号:
5265936 - 财政年份:2000
- 资助金额:
$ 1.54万 - 项目类别:
Priority Programmes
TB ANTIGEN TARGETING TO ENHANCE T CELL RESPONSE
靶向结核抗原以增强 T 细胞反应
- 批准号:
2882120 - 财政年份:1999
- 资助金额:
$ 1.54万 - 项目类别:
TB ANTIGEN TARGETING TO ENHANCE T CELL RESPONSE
靶向结核抗原以增强 T 细胞反应
- 批准号:
2413472 - 财政年份:1998
- 资助金额:
$ 1.54万 - 项目类别:














{{item.name}}会员




